{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:24:29Z","timestamp":1791944669097,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.amjcard.2025.07.022","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T22:20:20Z","timestamp":1752963620000},"page":"89-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Outcomes"],"prefix":"10.1016","volume":"256","author":[{"given":"Abhishek","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Creechan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waiel","family":"Abusnina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank","family":"Rappaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsik","family":"Ben-Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder D.","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell F.","family":"Satler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-9226","authenticated-orcid":false,"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2025.07.022_bib0001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.carrev.2016.10.005","article-title":"A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis","volume":"18","author":"Westman","year":"2017","journal-title":"Cardiovascular Revascularization Medicine"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0002","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0003","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0004","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0006","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0007","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0008","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0009","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijcard.2018.11.114","article-title":"Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb\/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial","volume":"278","author":"Abtan","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscai.2024.102294","article-title":"SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI","volume":"3","author":"Tamis-Holland","year":"2024","journal-title":"Journal of the Society for Cardiovascular Angiography & Interventions"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024513","article-title":"Cangrelor Use Patterns and Transition to Oral P2Y(12) Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry","volume":"11","author":"Rymer","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"5","author":"Grimfj\u00e4rd","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133280","article-title":"Gender disparities in cangrelor usage for the treatment of patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"432","author":"Abusnina","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0016","first-page":"1188","article-title":"Lack of Racial Disparities in Cangrelor Therapy in Patients Presenting With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention","volume":"105","author":"Abusnina","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0017","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.amjcard.2019.01.031","article-title":"Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention","volume":"123","author":"Hideo-Kajita","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37084-2","article-title":"Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry","volume":"13","author":"Pepe","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0019","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.carrev.2020.01.021","article-title":"Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment","volume":"21","author":"Shlofmitz","year":"2020","journal-title":"Cardiovascular Revascularization Medicine"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64652-x","article-title":"A dual-center analysis of conservative versus liberal glycoprotein IIb\u2013IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction","volume":"14","author":"Callichurn","year":"2024","journal-title":"Scientific Reports"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0021","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacc.2016.10.055","article-title":"Cangrelor With and Without Glycoprotein IIb\/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2021.04.013","article-title":"Cangrelor vs. glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention","volume":"238","author":"Yerasi","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2025.07.022_bib0023","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","article-title":"Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"284","author":"Bhatt","year":"2000","journal-title":"Jama"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925004199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925004199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:55:04Z","timestamp":1763171704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925004199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"alternative-id":["S0002914925004199"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.07.022","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Outcomes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}